SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer.
Evan Y. Yu
Research Funding - ImClone Systems; Veridex
Catherine M. Tangen
No relevant relationships to disclose
Celestia S. Higano
Research Funding - ImClone Systems
Neeraj Agarwal
Consultant or Advisory Role - Exelixis (U); Medivation (U)
Honoraria - Dendreon
Research Funding - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Medivation; Novartis; Pfizer; Takeda
Sumanta Kumar Pal
No relevant relationships to disclose
Ajjai Shivaram Alva
No relevant relationships to disclose
Elisabeth I. Heath
No relevant relationships to disclose
Elaine Tat Lam
Consultant or Advisory Role - Exelixis
Research Funding - Astellas Pharma; Bayer Schering Pharma; Exelixis; Janssen Pharmaceutical
Shilpa Gupta
No relevant relationships to disclose
Michael B. Lilly
No relevant relationships to disclose
Yoshio Inoue
No relevant relationships to disclose
Kim N. Chi
No relevant relationships to disclose
Nicholas J. Vogelzang
Consultant or Advisory Role - Veridex
Honoraria - Veridex
David I. Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Medivation; Novartis; Pfizer; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Medivation; Novartis; Pfizer; Prometheus; Teva
Research Funding - Millennium; Sanofi
Expert Testimony - Medivation
Hongli Li
No relevant relationships to disclose
Heather H. Cheng
No relevant relationships to disclose
Stephen R Plymate
No relevant relationships to disclose
Maha Hussain
Research Funding - ImClone Systems
Ian Murchie Thompson
No relevant relationships to disclose